Tempus AI (NASDAQ:TEM) Stock Price Down 1.4% – What’s Next?

Tempus AI, Inc. (NASDAQ:TEM) shares fell 1.4% on Tuesday . The stock traded as low as $58.35 and last traded at $58.16. 6,469,384 shares traded hands during trading, a decline of 53% from the average session volume of 13,663,560 shares. The stock had previously closed at $59.00.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on TEM shares. Guggenheim reiterated a “buy” rating on shares of Tempus AI in a report on Tuesday, February 25th. Loop Capital lowered their target price on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday, January 14th. Wolfe Research lowered Tempus AI from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 26th. Morgan Stanley upped their price objective on shares of Tempus AI from $50.00 to $60.00 and gave the company an “overweight” rating in a report on Thursday, March 6th. Finally, JPMorgan Chase & Co. cut Tempus AI from an “overweight” rating to a “neutral” rating and raised their target price for the stock from $50.00 to $55.00 in a research note on Tuesday, February 25th. Six equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $61.18.

Tempus AI Stock Down 2.1 %

The company has a 50 day simple moving average of $57.78 and a 200 day simple moving average of $51.47. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69.

Insider Transactions at Tempus AI

In other Tempus AI news, CAO Ryan M. Bartolucci sold 13,770 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $60.00, for a total transaction of $826,200.00. Following the transaction, the chief accounting officer now owns 57,237 shares in the company, valued at approximately $3,434,220. The trade was a 19.39 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Ryan Fukushima sold 20,000 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $39.61, for a total value of $792,200.00. Following the completion of the transaction, the chief operating officer now owns 982,442 shares of the company’s stock, valued at $38,914,527.62. The trade was a 2.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,598,969 shares of company stock worth $317,194,162 over the last 90 days.

Institutional Trading of Tempus AI

Several hedge funds and other institutional investors have recently made changes to their positions in TEM. Wells Fargo & Company MN increased its holdings in Tempus AI by 13.2% in the fourth quarter. Wells Fargo & Company MN now owns 2,384 shares of the company’s stock valued at $80,000 after buying an additional 278 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Tempus AI by 0.4% in the 3rd quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock worth $7,537,000 after acquiring an additional 539 shares during the period. Operose Advisors LLC acquired a new position in Tempus AI during the fourth quarter worth about $25,000. Prestige Wealth Management Group LLC lifted its holdings in shares of Tempus AI by 910.4% in the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after purchasing an additional 965 shares in the last quarter. Finally, Farther Finance Advisors LLC acquired a new stake in shares of Tempus AI in the fourth quarter valued at approximately $34,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.